Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyperactivity disorder(ADHD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bundang CHA Hospital
• Collaborator: Hallym University Medical Center
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• ADHD

• Must be able to swallow a capsule

Exclusion Criteria:

• Pervasive developmental disorder

• Mental retardation

• Psychotic disorder

• Bipolar disorder

• Suicidality

• Neurological disorder

• Concurrent psychiatric treatment